Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Radioactive substances, such as samarium 153, may release radiation as it breaks
down and kill cancer cells. Bortezomib may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth. Bortezomib may also make tumor cells more sensitive to
radiation. Giving samarium 153 together with bortezomib may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of samarium 153 when
given together with bortezomib in treating patients with relapsed or refractory multiple
myeloma.